Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
), nerve-sparing prostatectomy (n = 675), external beam radiation therapy (EBRT; n = 261), or low-dose-rate brachytherapy (n = 87) for men with favorable-risk disease and treatment with prostatectomy (n = 402) or EBRT with androgen deprivation therapy (n = 217) for men with unfavorable-risk disease.Patient-reported function, based on the 26-item Expanded Prostate Index Composite (range, 0-100), 5 years after treatment. Regression models were adjusted for baseline function and patient and tumor (...) , 12.5 [95% CI, 6.2-18.7]) and incontinence at each time point through 5 years (adjusted mean difference, 23.2 [95% CI, 17.7-28.7]), than prostatectomy.In this cohort of men with localized prostatecancer, most functional differences associated with contemporary management options attenuated by 5 years. However, men undergoing prostatectomy reported clinically meaningful worse incontinence through 5 years compared with all other options, and men undergoing prostatectomy for unfavorable-risk disease
Micro-Ultrasound Imaging for Accuracy of Diagnosis in Clinically Significant ProstateCancer: A Meta-Analysis. Background: Prostatecancer is a frequently diagnosed malignant solid tumor in men. The accuracy of diagnosis is becoming increasingly important. This meta-analysis evaluated the accuracy of micro-ultrasound in the diagnosis of clinically significant prostatecancer. Methods: We searched PubMed, Embase, Web of Science, and Cochrane Library databases to recruit studies in English (...) . The quality assessment of diagnostic accuracy studies-2 protocol was used to evaluate the literature quality. Publication bias was analyzed using Deeks' funnel plot asymmetry test. We calculated the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and 95% confidence interval (95% CI) for studies of micro-ultrasound imaging for prostatecancer. The results were assessed by the summary receiver-operating characteristic curve
Re: A systematic review of contemporary management of oligometastatic prostatecancer: fighting a challenge or tilting at windmills? From Slaoui et al., World J urol 2019. Long-term safety of local radiation therapy of newly diagnosed low burden metastati 30879124 2019 12 30 2020 01 10 1433-8726 37 11 2019 11 World journal of urology World J Urol Re: A systematic review of contemporary management of oligometastatic prostatecancer: fighting a challenge or tilting at windmills? From Slaoui et al (...) ., World J urol 2019. Long-term safety of local radiation therapy of newly diagnosed low burden metastatic prostatecancer: an unaddressed concern. 2541-2542 10.1007/s00345-019-02714-w Rocco Bernardo B Department of Urology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. firstname.lastname@example.org. Chiara Sighinolfi Maria SM http://orcid.org/0000-0001-7211-0485 Department of Urology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. eng
A meta-analysis of influence of MSMB promoter rs10993994 polymorphisms on prostatecancer risk. The aim of this meta-analysis was to assess the association between beta-microseminoprotein gene (MSMB) rs10993994 polymorphism and prostatecancer (PCa) risk.Relevant databases were searched to identify studies investigating the association between rs10993994 polymorphisms and the risk of PCa using allele contrast, recessive, dominant, and additive models. The assessment of the association was used
Association between human papillomavirus infection and prostatecancer: A global systematic review and meta-analysis. Although an increasing number of studies have been conducted to evaluate the association between human papillomavirus (HPV) infections and distribution of HPV types worldwide with the risk of prostatecancer (PC), the results remain inadequate. Hence, we investigated the association between HPV infection and PC risk using a meta-analysis. Relevant studies from January 1990 (...) to December 2016 were searched in PubMed, Web of sciences, and Scopus databases. Pooled odds ratio (OR) and their corresponding 95% confidence interval (CI) were calculated to find the association between the prevalence of HPV and prostatecancer risk. To do so, data from 24 studies with 5546 prostatecancer cases were pooled in order to evaluate the heterogeneity of chief parameters including study region, specimen type, HPV DNA source, detection technique, publication calendar period, and Gleason score
Effect of metformin on the risk of prostatecancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies. Preclinical studies have suggested the antitumorigenic properties of metformin on prostatecancer; results from epidemiological studies remain contradictory. We aim to investigate the evidence of metformin and the risk of prostatecancer. PubMed, Embase, Cochrane Library, and Web of Science databases were searched (...) for eligible studies. Meta-analyses were carried out using the most fully adjusted hazard ratios and the corresponding 95% confidence intervals. Eighteen cohort studies and six case-control studies representing 2 009 504 male patients with type 2 diabetes mellitus were identified. The pooled HR of prostatecancer for metformin therapy was 0.97 (0.84-1.12) in case-control studies and 0.94 (0.79-1.12) in cohort studies, respectively. In cohort studies, we found that there was a modest association in studies
Non-Gaussian models of diffusion weighted imaging for detection and characterization of prostatecancer: a systematic review and meta-analysis. The importance of Diffusion Weighted Imaging (DWI) in prostatecancer (PCa) diagnosis have been widely handled in literature. In the last decade, due to the mono-exponential model limitations, several studies investigated non-Gaussian DWI models and their utility in PCa diagnosis. Since their results were often inconsistent and conflicting, we performed
score. Genomic alterations of TNC was also significantly associated (P < 0.05) with expression level of genes from NOTCH, SOX and WNT family, implicating a link between TNC and poorly differentiated aggressive phenotype in NEPC. TCGA prostateadenocarcinoma cases with TNC alteration also demonstrated prominent decrease in disease-free survival (P = 0.0637). These findings indicate a possible association of TNC to the aggressive subtype of prostatecancer and warrant further functional studies (...) Genomic alterations of Tenascin C in highly aggressive prostatecancer: a meta-analysis. Tenascin C (TNC), an extra-cellular matrix (ECM) family gene, is expressed in several cancer tissues of breast, lung, colon, and gastrointestinal tract leading to proliferation, migration, invasion, angiogenesis and metastasis, but its role in tumorigenesis of prostatecancer is poorly understood. We took a meta-analysis approach to characterize the alterations of TNC gene in prostatecancer using publicly
Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for ProstateCancer: A Systematic Review. Evidence-based guidelines for active surveillance (AS), a treatment option for men with low-risk prostatecancer, recommend regular follow-up at periodic intervals to monitor disease progression. However, gaps in monitoring can lead to delayed detection of cancer progression, leading to a missed window of curability.We aimed to identify (...) the extent to which real-world observational studies reported adherence to monitoring protocols among prostatecancer patients on AS. When reported, we sought to characterize definitions of adherence.We systematically reviewed observational studies assessing outcomes of prostatecancer patients on AS, published before March 22, 2019 in PubMed, Embase, and CENTRAL. Adherence definitions were considered time bound if they included prespecified time and binary if adherence was assessed but did not specify
Correlation between Prostatitis, Benign Prostatic Hyperplasia and ProstateCancer: A systematic review and Meta-analysis. Background: No consensus has been reached on the definite associations among prostatitis, benign prostatic hyperplasia (BPH) and prostatecancer (PCa). Hence, this meta-analysis was conducted to explore their triadic relation by summarizing epidemiological evidence. Methods: Systematical and comprehensive retrieval of online databases PubMed, PMC, EMBASE and Web of Science (...) was performed to acquire eligible studies, up to April 1st, 2019. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to clarify their correlations. Results: A total of 42 studies were enrolled in the quality assessment and 35 were finally included in the meta-analyses. Among them, 27 studies were included to describe the association between prostatitis and PCa (OR=1.72, 95% CI=1.44-2.06, I2 =90.1%, P<0.001). 21 studies presented significant evidence about the relation between BPH
Interactive, Up-to-date Meta-Analysis of MRI in the Management of Men with Suspected ProstateCancer. The aim of this study was to test an interactive up-to-date meta-analysis (iu-ma) of studies on MRI in the management of men with suspected prostatecancer. Based on the findings of recently published systematic reviews and meta-analyses, two freely accessible dynamic meta-analyses (https://iu-ma.org) were designed using the programming language R in combination with the package "shiny (...) ." The first iu-ma compares the performance of the MRI-stratified pathway and the systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostatecancer, while the second iu-ma focuses on the use of biparametric versus multiparametric MRI for the diagnosis of prostatecancer. Our iu-mas allow for the effortless addition of new studies and data, thereby enabling physicians to keep track of the most recent scientific developments without having to resort
, and 230 deaths (49% of the subgroup). Median overall survival was not presented, HR=0.54 (95%CI: 0.41 to 0.70). The Kaplan Meier survival estimates at 36 months were 65% and 45% in the abiraterone and ADT groups respectively. 6, 7 A total of 283 patients (60%) had experienced disease progression, HR= 0.46 (95%CI: 0.36 to 0.59). 6 An opportunistic comparison of patients with high risk locally advanced or metastatic hormone-naïve prostatecancer who had been randomised to receive the abiraterone regimen (...) and responds to treatment that decreases androgen levels. 4 Prognostic factors for high risk disease include a PSA greater than 20ng/mL; having a tumour affecting both sides of the prostate gland and having a Gleason score of 8 to 10. Due to the nature of the disease, the majority of patients diagnosed with high risk mHSPC present with bone metastases, which increase the burden of disease and are a major cause of morbidity and mortality. 4 Treatment options include ADT with or without docetaxel (off-label
, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3- 18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostatecarcinoma. J Nucl Med. 2007;48:56–63. 6. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostatecancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. PractRadiatOncol. 2018;8:28–39. 7. Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport (...) acid, a potential tumor-seeking agent. J Nucl Med. 1979;20:1055–61. 3. ShoupTM OJ, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [ 18 F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8. 4. Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3- 18 F-fluorocyclobutyl-1-carboxylic acid for the detection of prostatecancer. J Nucl Med. 2007;48:46–55. 5. Schuster DM, Votaw JR
Montréal, Montreal, QC, Canada Cite as: Can Urol Assoc J 2019 December 5; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 *** Introduction Metastatic prostatecancer remains an incurable disease. In Canada, approximately 8% of men with prostatecancer are diagnosed de novo with metastatic disease, and, in 2018, roughly 1200 men were diagnosed with de novo metastatic prostatecancer (PC) (1). The mainstay of treatment for de novo metastatic PC is androgen (...) deprivation therapy (ADT) which is initially effective in almost all patients. Progression is inevitable however, heralded by a rise in PSA, increasing disease burden and/or worsening symptoms, a disease state called metastatic castration resistant prostatecancer (mCRPC). Men with de novo metastatic PC have a poor prognosis with an estimated median overall survival of approximately 3-4 years (2). This has only improved slightly even in the advent of improved management of mCRPC (2, 3). Compared to PC
to identify studies performing a head-to-head comparison of prostate MRI using a 1.5 or 3 T magnet with an ERC and with a BAC/PAC for staging T3 prostatecancer. Pooled sensitivity and specificity of all studies were plotted in a hierarchical summary receiver operating characteristic plot. The diagnostic performance of the two techniques in staging T3 disease was evaluated using bivariate random-effects meta-analysis.Eight studies comparing head-to-head prostate MRI with an ERC and with a BAC/PAC were (...) Head-to-head comparison of prostate MRI using an endorectal coil versus a non-endorectal coil: meta-analysis of diagnostic performance in staging T3 prostatecancer. To compare the diagnostic performance of prostate magnetic resonance imaging (MRI) with an endorectal coil (ERC) to performance without an ERC using either body-array (BAC) or pelvic phased-array coil (PAC) in staging T3 prostate cancer.An electronic search of the PUBMED and EMBASE databases was performed until 10 October 2018
Associations of telomere length in risk and recurrence of prostatecancer: A meta-analysis. Over the past decades, there is an increasing number of association studies of telomere length (TL) and the risk and recurrence of prostatecancer (PCa), but the results are inconsistent. Hence, we identify the relevant studies published in English on or before 10 January 2019 conducting a literature review in the electronic databases including PubMed, EMBASE and Cochrane Library. Twelve studies (with 19
Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostatecancer: a systematic review and meta-analysis. To evaluate the diagnostic accuracy of multiparametric MRI (mpMRI) for detecting extracapsular extension (ECE) in patients with prostatecancer (PCa).We searched MEDLINE, PubMed, Embase and the Cochrane library up to December 2018. We included studies that used mpMRI to differentiate ECE from organ-confined PCa with a combination of T2 weighted (...) studies that comprised 3374 participants were included. The pooled data showed a sensitivity of 0.55 (95% confidence interval 0.43, 0.66]) and specificity of 0.87 (95% confidence interval 0.82, 0.91) for extracapsular extension detection in PCa.First, our meta-analysis shows moderate sensitivity and high specificity for mpMRI to differentiate ECE from organ-confined prostatecancer before surgery. Second, our meta-analysis shows that mpMRI had no significant differences in performance compared
Is androgen deprivation therapy for prostatecancer associated with cardiovascular disease? A meta-analysis and systematic review. Androgen deprivation therapy (ADT) is widely being applied in men who suffered from prostatecancer. Whether androgen deprivation therapy (ADT) is associated with an increased risk of developing cardiovascular-related disease is poorly defined.The aim of the present meta-analysis is to explore the relationship between ADT and the risk of cardiac events. MATERIALS (...) group). In addition, the RR for risk of CVD was 1.28 (95% CI, 1.01-1.62, P < .05) for men with PCa on new hormonal agents.Various ADT modalities have different impact on cardiovascular disease risk in different level. Long-term application of ADT is not associated with increased risk of AMI and CVD. Both abiraterone and enzalutamide could significantly increase the incidence of cardiac events in patients who suffered from prostatecancer. Cautions and periodic cardiovascular elevation are necessary
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive ProstateCancer. There are many ongoing randomised trials of promising therapies for metastatic hormone-sensitive prostatecancer (mHSPC), but standard systematic reviews may not synthesise these in a timely or reliable way. We demonstrate how a novel approach to evidence synthesis is being used to speed up and improve treatment evaluations for mHSPC. This more prospective, dynamic (...) will be made available to other researchers for tackling new questions that might arise. The associated global, collaborative forum will aid strategic and harmonised development of the next generation of mHSPC trials (STOPCAP M1; http://www.stopcapm1.org). PATIENT SUMMARY: We report how a worldwide research effort will review results and anonymised data from advanced prostatecancer trials in new and different ways. We will work out, as quickly as possible, which advanced prostatecancer treatments